logo
Central team visits Odisha as 14 deaths reported in cholera outbreak

Central team visits Odisha as 14 deaths reported in cholera outbreak

Hindustan Times15-06-2025
Bhubaneswar: A central team from Delhi, comprising officials from Indian Council of Medical Research, National Centre for Disease Control, World Health Organisation, and Food Safety and Standards Authority of India on Sunday visited Jajpur district of Odisha as 14 deaths were reported and 1,500 people were hospitalised following a cholera outbreak.
Four blocks and one urban local body in Jajpur district have been hit most by the outbreak which started from a community feast in the town attended by over 2,500 people. 'Out of the 41 faecal samples sent to the laboratory from Jajpur district, eight tested positive for Vibrio cholerae. However, the number of affected persons is being slowly decreasing,' said Nilakantha Mishra, director of Odisha's public health.
Officials said most of the affected are showing acute diarrhoeal disorders with many of them showing dehydration tendencies. The worst-affected areas in Jajpur include Danagadi, Korei, Rasulpur and Dharmasala blocks, with many requiring advanced care at facilities like SCB Medical College and Hospital in Cuttack.
State health minister Mukesh Mahaling said those in hospitals are doing fine. 'We have deployed an additional health team from SCB Medical College and Hospital to support the efforts here. We're taking every measure to prevent further outbreaks. I appeal people to seek medical attention immediately if they experience symptoms such as loose motion, vomiting, or abdominal pain, rather than consulting local quacks or medicine stores. Cholera outbreak is a major concern, and we need to take collective efforts to prevent its spread,' he said.
Meanwhile, leader of Opposition and former chief minister Naveen Patnaik said the state government must act vigilantly without pushing people's lives into further danger and take immediate strong measures to curb the spread of cholera. 'What had not been seen for many years has now disrupted public life in various districts. While cholera is spreading in Odisha, the state government's casual approach to it is shocking and disturbing to everyone,' he wrote on X.
Odisha last saw a cholera outbreak in December 2023 in Rourkela town where 11 people died and more than 1,800 were hospitalised. Similarly, in Rayagada district, an outbreak was reported between July and November 2022, with 10 deaths and 414 cases.
Cholera has consistently made its presence known in Odisha over the past two and a half decades, this persistent occurrence marks it as a significant public health issue, particularly affecting the lower socio-economic groups in the southern regions of Odisha. Between 2011 and 2020, Odisha had 19 outbreaks of cholera. Districts such as Rayagada, Koraput, Kalahandi, and Nuapada are particularly susceptible, making cholera a prominent and pressing concern for public health authorities in the region.
As a significant proportion of the human population in these cholera-prone areas relies on untreated water from environmental reservoirs, such as ponds, rivers, wells, nullahs, and ditches, for drinking, bathing, cooking, and agricultural activities, the widespread practice of using contaminated water sources serves as a major cause for the transmission of cholera infection. Despite efforts to raise awareness and education regarding the importance of safe water practices and the prevention of diarrheal diseases, cholera outbreaks continue to occur in Odisha.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway
Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway

Economic Times

time3 hours ago

  • Economic Times

Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway

The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax. ADVERTISEMENT AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. The vaccine aims to protect against human infection while also reducing vector-borne community transmission of the parasite. According to the release, the vaccine has demonstrated excellent efficacy in the preclinical stage of development. Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines, including broader protection by targeting two vulnerable parasite stages, lower risk of immune evasion, potential for better long-term immunity, and extended thermal stability with functionality maintained for over nine months at room is a recombinant multistage vaccine produced in Lactococcus lactis, designed to protect both individual humans and reduce the community transmission represents one of the most advanced malaria vaccine candidates globally, with a rational design targeting two key stages of the parasite. This vaccine consists of a stable and functional recombinant chimaera between antigenic components that promises dual protection. ADVERTISEMENT ICMR intends to license the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximise public health benefits. All collaborations will adhere to ICMR's Intellectual Property Policy. ADVERTISEMENT As an indigenously developed vaccine candidate that fulfils the Make in India mandate, AdFalciVax holds the potential to contribute substantially to malaria eradication by preventing infection and minimising community information is provided for awareness purposes only. The vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation. ADVERTISEMENT (You can now subscribe to our Economic Times WhatsApp channel)

ICMR invites EoIs for tech transfer to commercialise malaria vaccine
ICMR invites EoIs for tech transfer to commercialise malaria vaccine

Business Standard

time4 hours ago

  • Business Standard

ICMR invites EoIs for tech transfer to commercialise malaria vaccine

The Indian Council of Medical Research (ICMR) has invited expressions of interest (EoI) from eligible companies and manufacturers to undertake the transfer of technology for commercialisation of an indigenous recombinant multi-stage malaria vaccine candidate named AdFalciVax. The vaccine candidate, being developed by ICMR's Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB), aims to prevent plasmodium falciparum, a parasite which causes severe and fatal malaria, in humans and minimise its community transmission. According to the EoI, ICMR-RMRCBB will also provide expert guidance and technical support for the production of the vaccine in all phases, effectively accelerating its development and commercialisation. The agreement is proposed to be executed on a non-exclusive basis with single or multiple companies to enable wider outreach of the malaria vaccine for societal benefit and public health use. It added that the development may take at least seven years in four stages with each stage having a six-month buffer time. While ICMR would provide technical support through its team of experienced scientists in study planning and product development, the selected company would be responsible for obtaining all the regulatory approvals, starting from research and development (R&D) for product development to its commercialisation. The Council will also have no financial implications unless otherwise specified, however, its institutes would provide support and facilitation to conduct the R&D and clinical studies of new technology in India. The EoI adds that in case of transfer of technology, ICMR is the sole owner of the said technology, including any underlying Intellectual Properties and commercialisation rights. 'In case of collaboration between ICMR and the company for the joint development of the technology/product, the Background Intellectual Property (BGIP) shall always remain the sole and non-exclusive property of the party generating it,' the EoI said. As part of the agreement, the collaborating company will be required to share technical data with ICMR and participate in all discussions in a professional and mutually agreed-upon manner. 'Subsequent to the execution of the agreement, such companies/manufacturers shall be responsible to pay the royalty at the rate of 2 per cent on net sales, according to the ICMR Guidelines for Technology Development Collaboration,' the medical research body said. According to the World Health Organisation's (WHO) World Malaria Report 2024, India contributes half of all estimated cases in the South East Asia Region, which in turn accounts for 1.5 per cent of the global malaria burden. India currently has access to two WHO-recommended malaria vaccines, Mosquirix and R21/Matrix-M. While the former is manufactured by GlaxoSmithKline (GSK), the latter is manufactured by the Serum Institute of India (SII). Both vaccines are primarily for children in areas with moderate to high malaria transmission. 'Based on preclinical data, AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing single-stage malaria vaccines,' an official in the know said. The pre-clinical validation of the vaccine candidate was conducted in collaboration with the Indian Council of Medical Research-National Institute of Malaria Research, other constituent institutes of ICMR, and the National Institute of Immunology in Delhi, an autonomous research institute of the Department of Biotechnology.

ICMR invites EoIs to undertake tech transfer, commercialise malaria vaccine
ICMR invites EoIs to undertake tech transfer, commercialise malaria vaccine

Business Standard

time6 hours ago

  • Business Standard

ICMR invites EoIs to undertake tech transfer, commercialise malaria vaccine

The Indian Council of Medical Research (ICMR) has invited expressions of interest (EoIs) from eligible companies and manufacturers for the transfer of technology to commercialise an indigenous recombinant multi-stage malaria vaccine candidate, AdFalciVax. Developed by ICMR's Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB), AdFalciVax aims to prevent plasmodium falciparum infections in humans and reduce community transmission of the parasite, which causes severe and potentially fatal malaria. Non-exclusive tech transfer model proposed The EoI outlines a non-exclusive agreement to be executed with one or more companies, enabling broader outreach and public health access. ICMR-RMRCBB will offer expert guidance and technical support across all stages of production to facilitate development and commercialisation. The development process is expected to span at least seven years, divided into four stages, with a six-month buffer built into each stage. While ICMR will provide scientific and technical support, the selected companies will be responsible for securing all regulatory approvals—from research and development to final commercialisation. ICMR to retain IP and commercial rights The Council clarified that it would bear no financial liability unless otherwise specified. Its institutes will, however, facilitate R&D and clinical studies within India. In case of technology transfer, ICMR will retain sole ownership of the technology, including all underlying intellectual properties and commercial rights. For joint development projects, any Background Intellectual Property (BGIP) will remain the exclusive property of the party that generated it. Firms to pay royalty on net sales Participating companies must share technical data with ICMR and engage in all discussions professionally and in mutual agreement. 'Subsequent to the execution of the agreement, such companies/manufacturers shall be responsible to pay the royalty at the rate of 2 per cent on net sales, according to the ICMR Guidelines for Technology Development Collaboration,' the Council stated. India among top contributors to regional malaria cases According to the World Health Organisation's World Malaria Report 2024, India accounts for half of the estimated malaria cases in the South-East Asia Region, which contributes 1.5 per cent of the global malaria burden. India currently has access to two WHO-recommended malaria vaccines—Mosquirix, manufactured by GlaxoSmithKline (GSK), and R21/Matrix-M, made by the Serum Institute of India (SII). Both are primarily intended for children in regions with moderate to high malaria transmission. Broader protection potential cited An official familiar with the matter said AdFalciVax may offer broader protection and a lower risk of immune evasion compared to existing single-stage vaccines, based on preclinical data. Pre-clinical validation of AdFalciVax was carried out in collaboration with ICMR's National Institute of Malaria Research (NIMR), other ICMR institutes, and the National Institute of Immunology in Delhi, an autonomous institute under the Department of Biotechnology.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store